GU Cancers 2022 | Challenges in the field of PARPi treatment for mCRPC

Arpit Rao, MD, Baylor College of Medicine, Houston, TX, discusses the impact and challenges of treatment with PARP inhibitors (PARPi) from the PROpel (NCT03732820) and MAGNITUDE (NCT03748641) trials as PARPi translates into clinical practice for patients with metastatic castration-resistant prostate cancer (mCRPC). However, some unanswered questions still remain, including in regards to the side-effect profile which makes it difficult to provide patients with prolonged PARPi treatment, such as those who are hormone-sensitive. However, interrupted PAPRi could reduce the grade 3 toxicities associated with PARPi, including olaparib and niraparib, whilst maintaining treatment efficacy. This interview took place at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium 2022 in San Francisco, CA.